Sam Waksal moved quickly to secure two deals with Valeant Pharmaceuticals to secure rights to two therapies for hepatitis C for his new biotech company, Kadmon Pharmaceuticals. Kadmon gains rights to taribavirin for $5 M upfront plus milestones and royalties that scale from 8-12 percent. He further secured some right to ribavirin in Europe for $7.5 M. The deal is enabled to a large degree by Valeant's decision to move away from hepatitis C to focus in other therapeutic areas like CNS therapies. Kadmon continues to build its hepatitis C franchise. See Fierce Biotech and GEN accounts.
Posted by Bruce Lehr November 2nd 2010.
Comments